Corrigendum to “Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients”

Corrigendum to “Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients”

Saved in:

Bibliographic Details
Main Authors:	Long-Shan Ji, Qiu-Tian Gao, Ruo-Wen Guo, Xin Zhang, Zhen-Hua Zhou, Zhuo Yu, XiaoJun Zhu, Ya-Ting Gao, Xue-Hua Sun, Yue-Qiu Gao, Man Li
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2022/7931597
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Systematic review and meta-analysis of animal experiments on Bushen formulas for the treatment of polycystic ovary syndrome
by: Yiwei Cui, et al.
Published: (2025-03-01)

Experience of entecavir therapy in chronic hepatitis B
by: E. V. Esaulenko, et al.
Published: (2014-09-01)

Severe Acute Hepatitis B Treated with Entecavir
by: Giuseppe Vittorio Luigi De Socio, et al.
Published: (2011-03-01)

Severe Acute Hepatitis B Treated with Entecavir
by: Andrea Tosti, et al.
Published: (2011-01-01)

A study on the mechanism of Bushen Kaiqiao Formula in modulating microglial activation to alleviate neuroinflammation in ADHD
by: Jiaqi Zhang, et al.
Published: (2025-09-01)

Adherence to entecavir for chronic hepatitis B and correlation with effectiveness
by: Vanessa Romero Díaz-Maroto, et al.
Published: (2015-11-01)

A prospective randomized control study of Bushen Jianpi herb formula protecting residual renal function in patients with peritoneal dialysis
by: LUO Jian-hua, et al.
Published: (2015-01-01)

Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B
by: Hideo Takayama, et al.
Published: (2021-01-01)

Experience of entecavir in renal graft recipients with chronic hepatitis B
by: M. L. Zubkin, et al.
Published: (2011-09-01)

Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
by: Ming Shi, et al.
Published: (2015-01-01)

Mechanistic insights into the Bushen Huatan Huoxue Formula and its components in ameliorating obesity-associated polycystic ovary syndrome
by: Yu-Xin Jin, et al.
Published: (2025-07-01)

Entecavir in clinical practice
by: Editorial Article
Published: (2018-08-01)

Integrating network pharmacology and experimental validation to explore the mechanism of action of BushenQiangxin Formula for the treatment of chronic heart failure
by: Jinhua Pang, et al.
Published: (2025-03-01)

Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
by: Weixia Ke, et al.
Published: (2014-01-01)

The Inhibitory Effect of the Active Ingredients in the Bushen Huoxue Formula on the IL-17A Signaling Pathway and Its Alleviating Effect on Osteoarthritis
by: Wang X, et al.
Published: (2025-05-01)

Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
by: Chenxia Sheng, et al.
Published: (2020-01-01)

Effect of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamideantiviral Therapy on Renal Function in Chronic Hepatitis B Patients: A Real-World Retrospective Study
by: Li Y, et al.
Published: (2025-02-01)

Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B
by: Beatriz López Centeno, et al.
Published: (2016-07-01)

Entecavir: stability and drug-excipient compatibility
by: Ariadne Botto Fiorot, et al.
Published: (2025-01-01)

Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients
by: Jinman Shao, et al.
Published: (2021-01-01)

Bushen Huoxue formula protects against renal fibrosis and pyroptosis in chronic kidney disease by inhibiting ROS/NLRP3-mediated inflammasome activation
by: Lin Liao, et al.
Published: (2024-12-01)

Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
by: Takuya Matsubara, et al.
Published: (2025-01-01)

Corrigendum: Characterization of the hepatic flora and metabolome in nonalcoholic fatty liver disease
by: Hua Jiang, et al.
Published: (2025-04-01)

Corrigendum: Tracheobronchomegaly associated with tracheobronchopathia osteochondroplastica: a case report
by: Zhen Hua Li, et al.
Published: (2024-12-01)

Screening of Human Milk Oligosaccharide Combinations for Immunomodulatory Activity and Immunomodulatory Effects of Milk Formula Containing Them on Mice
by: MENG Liping, YANG Chang, XU Xiaomin, WANG Meihua, SHI Hanxu, YE Wanyun, LIU Siyuan, QIAN Wentao, LI Hongliang, XU Yajun
Published: (2025-06-01)

Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis
by: Shi-Jia Liu, et al.
Published: (2025-02-01)

Validation of quantitative hepatitis B virus DNA and hepatitis B e antigen titers in patients of chronic hepatitis B virus infection on entecavir therapy at tertiary care hospital
by: Diksha Budhani, et al.
Published: (2025-01-01)

Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients
by: Huiqing Liang, et al.
Published: (2025-05-01)

Need of Treatment Modification During Entecavir Therapy in Patients with Chronic Hepatitis B: Long-Term Follow-Up Results for 120 Months
by: Hae Rim Kim, et al.
Published: (2025-01-01)

Computation Simulation Research of Bushen Zhuangjin Decoction on Multi-target Effects in Delaying Cataplasia of Articular Cartilage
by: Chunsong ZHENG, et al.
Published: (2018-04-01)

Improvement in renal function after switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low estimated glomerular filtration rates
by: Liang Wang, et al.
Published: (2025-07-01)

Mechanism of Follicular Helper T Cell Differentiation Regulated by Transcription Factors
by: Long-Shan Ji, et al.
Published: (2020-01-01)

Low-Content Quantitation in Entecavir Tablets Using 1064 nm Raman Spectroscopy
by: Yanlei Kang, et al.
Published: (2020-01-01)

Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.
by: Yi Lin, et al.
Published: (2025-01-01)

Hepatoprotective and anti-inflammatory effects of entecavir or probiotics on Oxaliplatin-Induced Liver Injury in the rats.
by: Asem A. Askandar, et al.
Published: (2023-09-01)

Tenofovir disoproxil fumarate versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis
by: Yong Wang, et al.
Published: (2025-05-01)

HBx mutant-regulated RPL13AP25 mediates suboptimal virological response to entecavir and HCC progression
by: Yang-Hsiang Lin, et al.
Published: (2025-06-01)

Corrigendum: Regulation of the immune microenvironment by SUMO in diabetes mellitus
by: Yuting Zhuo, et al.
Published: (2025-05-01)

Corrigendum: A report of 12 cases of congenital hepatic hemangioma and literature review
by: Ying Wei, et al.
Published: (2025-06-01)

Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice
by: Yan Liu, et al.
Published: (2019-01-01)